Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
SubB2M CA15-3
SubB2M CA125
Exo-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
10-Sep-2018
Ceasing to be a substantial holder
6-Sep-2018
Bard1 Ovarian Test Results
31-Aug-2018
Appendix 4E
21-Aug-2018
Final Director's Interest Notice
13-Aug-2018
Death of Non-Executive Director
1-Aug-2018
Quarterly Activities Report and Appendix 4C
12-Jul-2018
US Patent Issued Protecting BARD1 Ovarian Test
21-Jun-2018
Appendix 3B Release of Securities from Escrow
19-Jun-2018
Improved Performance of BARD1 Ovarian Test
8-Jun-2018
Notice under ASX Listing Rule 3.10A
Previous
1
2
3
4
5
6
Next